Want to track ESPR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Zacks | 1 year ago
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
Zacks | 2 years ago
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance.
Seekingalpha | 2 years ago
